Cover Image
市場調查報告書

EpiCast Report:全球老年癡呆症的免疫學的預測

EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2026

出版商 GlobalData 商品編碼 262491
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:全球老年癡呆症的免疫學的預測 EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2026
出版日期: 2017年10月12日 內容資訊: 英文 37 Pages
簡介

全球的60歲以上的人口佔的癡呆症患者的比率為3.9%,老年癡呆症的患病者的比率,美國為9.7%,歐洲為4.4%,發展中國家為3.4%。全球各國老年癡呆症的患病人數今後將劇增。全球主要9個國家的患病人數,從2012年的1253萬人,2022年以年平均(年複合成長率)3.35%的迅速速度增加到1672萬人。

本報告提供全球主要9個國家(美國·德國·法國·義大利·西班牙·英國·日本·中國·印度)的克隆氏症的發病情形與今後預測相關分析,血脂異常症的特徵,及各國的詳細內容,今後10年的發病數量·患病人數的預測值等等的調查評估,並將其結果為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 免疫學

  • 風險要素和合併症
    • 老年癡呆症的家族病史提高到7.5倍風險
    • ApoE ε4 等位基因使老年癡呆症的風險提高3倍
    • 心血管疾病的風險因素,使老年癡呆症的風險倍增
    • 65歲以上老年癡呆症的發病數量·患病人數每5歲倍增
    • 糖尿病男性的發病風險提高2倍,女性的情況微增
    • 女性的發病風險比起男性高1.5倍
    • 輕度認知功能障礙(MCI)提高老年癡呆症的風險
    • 憂鬱症使老年癡呆症的風險增加到三倍,但也有是單純疾病階段的情況
    • 老年癡呆症患者的最大70%也受困於焦慮症
    • 精神病和躁動,是老年癡呆症患者的一般併發症
  • 全球各國趨勢
    • 美國
    • 歐洲主要5個國家
    • 日本
    • 中國
    • 印度
  • 預測手法
    • 利用的資訊來源
    • 預測的前提條件與手法
    • 未利用的資訊來源
  • 免疫學的預測(今後10年)
    • 老年癡呆症的患病人數
    • 各年齡層的患病人數
    • 男女的患病人數
    • 以年齡標準化的患病人數
  • 議論
    • 免疫學趨勢的相關結論
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER162-17

Alzheimer's disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly, characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities, such as thinking, language, and learning capacity (NIA, 2017). AD is the most common cause of dementia in people age 60 years and older, and accounts for approximately 75% of the total dementia cases worldwide.

To forecast the total prevalent cases of AD in adults ages 60 years and older in the 7MM during the forecast period (2016-2026), our epidemiologists identified country-specific population-based studies that used the diagnostic criteria based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV) to diagnose dementia, and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria to diagnose AD.

In the 7MM, our epidemiologists forecast an increase in the total prevalent cases of AD from around 10.6 million total prevalent cases in 2016 to around 13.7 total prevalent cases in 2026, at an annual growth rate (AGR) of nearly 3% during the forecast period. Among the 7MM, the US will have the highest number of total prevalent cases of AD throughout the forecast period, while the UK will have the lowest.

Similarly, our epidemiologists forecast that the total prevalent cases of MCI in the 7MM will increase from over 28 million total prevalent cases in 2016 to around 34.5 million total prevalent cases in 2026 at an AGR of about 2%. Among the 7MM, the US will have the highest number of total prevalent cases of MCI throughout the forecast period, while Spain will have the lowest.

The report "EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and the global and historical trends for AD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the total prevalent cases of AD (diagnosed and undiagnosed) segmented by sex, age (ages 60 years and older), and severity in these markets. Additionally, the report includes a 10-year epidemiological forecast for the total prevalent cases of MCI segmented by sex and age (ages 60 years and older) in these markets.

Scope

  • The Alzheimer's Disease (AD) EpiCast Report provides an overview of the risk factors and global trends of AD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of AD (diagnosed and undiagnosed) segmented by sex, age (ages 60 years and older), and severity in these markets. Additionally, the report includes a 10-year epidemiological forecast for the total prevalent cases of mild cognitive impairment (MCI) segmented by sex and age (ages 60 years and older) in these markets.
  • The AD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Alzheimer's Disease EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global AD market.
  • Quantify patient populations in the global AD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AD therapeutics in each of the markets covered.
  • Understand severity of prevalent AD cases and total prevalent cases of MCI.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Executive Summary 4

  • 2.1 Related Reports 6
  • 2.2 Upcoming Reports 6

3 Epidemiology 7

  • 3.1 Disease Background 7
  • 3.2 Risk Factors and Comorbidities 8
  • 3.3 Global and Historical Trends 9
  • 3.4 Forecast Methodology 11
    • 3.4.1 Sources 11
    • 3.4.2 Forecast Assumptions and Methods 14
    • 3.4.3 Total Prevalent Cases of AD 14
    • 3.4.4 Total Prevalent Cases of AD by Severity 17
    • 3.4.5 Total Prevalent Cases of MCI 20
  • 3.5 Epidemiological Forecast for AD (2016-2026) 22
    • 3.5.1 Total Prevalent Cases of AD 22
    • 3.5.2 Age-Specific Total Prevalent Cases of AD 23
    • 3.5.3 Sex-Specific Total Prevalent Cases of AD 24
    • 3.5.4 Total Prevalent Cases of AD by Severity 25
  • 3.6 Epidemiological Forecast for MCI (2016-2026) 26
    • 3.6.1 Total Prevalent Cases of MCI 26
    • 3.6.2 Age-Specific Total Prevalent Cases of MCI 27
    • 3.6.3 Sex-Specific Total Prevalent Cases of MCI 28
  • 3.7 Discussion 29
    • 3.7.1 Epidemiological Forecast Insight 29
    • 3.7.2 Limitations of Analysis 29
    • 3.7.3 Strengths of Analysis 30

4 Appendix 31

  • 4.1 Bibliography 31
  • 4.2 About the Authors 35
    • 4.2.1 Epidemiologist 35
    • 4.2.2 Reviewers 35
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 36
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 36
  • 4.3 About GlobalData 37
  • 4.4 Contact Us 37
  • 4.5 Disclaimer 37

List of Tables

1.1 List of Tables

  • Table 1: DSM-IV Criteria for the Diagnosis of Dementia 8
  • Table 2: NINCDS-ADRDA Criteria for the Diagnosis of AD 8
  • Table 3: Risk Factors and Comorbidities for AD 9
  • Table 4: 7MM, Total Prevalent Cases of AD, Both Sexes, Ages ≥60 Years, Selected Years 2016-2026. 22
  • Table 5: 7MM, Total Prevalent Cases of MCI, Both Sexes, Ages ≥60 Years, Selected Years 2016-2026. 26

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of AD, Both Sexes, Ages ≥60 Years, 2016 and 2026 5
  • Figure 2: 7MM, Total Prevalent Cases of MCI, Both Sexes, Ages ≥60 Years , 2016 and 2026 5
  • Figure 3: 7MM, Age-Standardized Total Prevalence of AD (%), Ages ≥60 Years 10
  • Figure 4: 7MM, Age-Standardized Total Prevalence of MCI (%), Ages ≥60 Years 11
  • Figure 5: 7MM, Sources Used and Not Used, Total Prevalent Cases of AD 12
  • Figure 6: 7MM, Sources Used, Total Prevalent Cases of AD by Severity 13
  • Figure 7: 7MM, Sources Used, Total Prevalent Cases of MCI 14
  • Figure 8: 7MM, Age-Specific Total Prevalent Cases of AD, Both Sexes, 2016 23
  • Figure 9: 7MM, Sex-Specific Total Prevalent Cases of AD, Both Sexes, Ages >60 Years, 2016 24
  • Figure 10: 7MM, Total Prevalent Cases of AD by Severity, Both Sexes, Ages ≥60 Years, 2016 25
  • Figure 11: 7MM, Age-Specific Total Prevalent Cases of MCI, Both Sexes, 2016 27
  • Figure 12: 7MM, Sex-Specific Total Prevalent Cases of MCI, Both Sexes, Ages >60 Years, 2016 28
Back to Top